Systemic Therapy for Psoriasis

Melvin Lee, MD; Robert E. Kalb, MD


Dermatology Nursing. 2008;20(2):105-111. 

In This Article

Adalimumab (Humira®)

Adalimumab is a monoclonal antibody against TNF. It is approved for the treatment of psoriatic arthritis, rheumatoid arthritis, and ankylosing spondylitis, and was recently approved for the treatment of psoriasis. The approved dose for psoriasis is 80 mg at week 0, then 40 mg 1 week later, and then 40 mg every other week. Phase III trials showed excellent results in the treatment of psoriasis (Menter, Papp, et al., 2007). A placebo-controlled trial comparing methotrexate to adalimumab revealed a significant advantage with adalimumab (Saurat et al., 2006).

Patients may develop an injection site reaction with adalimumab. Serious reactions include serious infections (including tuberculosis), demyelinating disease, bone marrow suppression, and an increased incidence of malignancy.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.